MARKET WIRECNN • 17h ago
symbol__ Stock Quote Price and ForecastCNN report covering Annexon Inc. (ANNX) market action, institutional positioning, and fundamental catalysts.
Why ANNX Stock advanced +1.00% Today — RQD Quant Desk Flash
$4.05 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.05
Annexon Inc. (ANNX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $767.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ANNX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ANNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Annexon Inc. (NASDAQ: ANNX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.05 (+1.00% 1D, market cap $767.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANNX ranks #791 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ANNX compare to HELP and COLL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANNX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $774.1M) and COLL (Collegium Pharmaceutical Inc.) posts a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $774.8M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ANNX?
▼
Per ANNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528115), Annexon Inc. generated $0 in revenue, -$206.7M in net income, and -$186.5M in free cash flow against $277.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.05 (-0.01%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANNX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY ANNX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.83+0% Next Q
22
Q2 (-2Q)Grade E$3.83-1.8% Next Q
25
Q3 (-1Q)Grade E$3.76+7.7% Next Q
27
CurrentGrade E$4.05-9.6% Hist 90D α
30
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ANNX Turnaround Squeeze
While ANNX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.16) and Max Pain ($4.25) forces dealer call-delta covering toward $7.54.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ANNX Stock advanced +1.00% Today — RQD Quant Desk Flash
Annexon Inc. (ANNX) advanced +1.00% to $4.05, trading at 33% of its 52-week range ($2.54 – $7.18). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 33% of its 52-week range ($2.54 – $7.18) with RSI-14 at 52.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.05 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ANNX Headlines & Catalysts
MARKET WIREMoomoo • 20h ago
Annexon(ANNX) Stock Options Chain | Quotes & NewsMoomoo report covering Annexon Inc. (ANNX) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 23h ago
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth CarefullySimply Wall St report covering Annexon Inc. (ANNX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 5d ago
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II TrialBRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im
MARKET WIREBenzinga • 6d ago
Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor EventCompany management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will
CATALYSTBenzinga • 15d ago
Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For MondayAnalysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
CATALYSTBenzinga • 15d ago
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
MARKET WIREYahoo • 17d ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANNX)
- ✓Walkthrough of ANNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ANNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.82%⚡ TESTING RESISTANCE
2026-11-03O $4.01H $4.05L $4.01C $4.05VOL 2.84M
RES: $4.12SUP: $3.20SMA50: $4.16SMA200: $5.20
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ANNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ANNX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ANNX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANNX)
Health Care Rank #791 of 1016
⚔️ HELP vs ANNX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ANNX vs. HELP, COLL, ARDX, AVBP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Annexon Inc. (ANNX) ranks #791 by composite RQD confidence (30/100, grade E) and #388 by equity capitalization ($767.8M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with ANNX at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANNX
ACTIVE
Annexon Inc. | E | 30/100 | — | — | -35.0% | +1.00% | $767.8M | Benchmark Subject |
| HELP Helus Pharma Inc. | D+ | 53/100 | — | — | — | -1.07% | $774.1M | /help-vs-annx → |
| COLL Collegium Pharmaceutical Inc. | C- | 59/100 | 12.4x | 59.3% | 85.0% | -0.96% | $774.8M | /coll-vs-annx → |
| ARDX Ardelyx Inc. | E | 24/100 | — | 90.3% | -32.7% | -2.26% | $755.0M | /ardx-vs-annx → |
| AVBP ArriVent BioPharma Inc. | E | 29/100 | — | — | -35.0% | -6.77% | $733.2M | /avbp-vs-annx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001528115In its most recent audited fiscal period (FY2025, filed 2025-12-31), Annexon Inc. (ANNX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$206.7M, operating cash flow of -$186.4M, and free cash flow of -$186.5M (-58.0% YoY). On the balance sheet, ANNX closed FY2025 with $277.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$206.7M | -$186.4M | -$186.5M | $277.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$138.2M | -$118.0M | -$118.0M | $350.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$134.2M | -$121.1M | -$121.1M | — | — |
3. ANNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ANNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Annexon Inc. (NASDAQ: ANNX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.05 (+1.00% 1D, market cap $767.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANNX ranks #791 in composite RQD confidence.
How does ANNX compare to HELP and COLL in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANNX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $774.1M) and COLL (Collegium Pharmaceutical Inc.) posts a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $774.8M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ANNX?
Per ANNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528115), Annexon Inc. generated $0 in revenue, -$206.7M in net income, and -$186.5M in free cash flow against $277.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ANNX trading relative to its 50-day, 200-day, and 52-week technical levels?
ANNX last traded at $4.05 (+1.00% on volume of 2,840,298 shares), positioning the stock -2.64% below its 50-day simple moving average ($4.16) and -22.12% below its 200-day simple moving average ($5.20). Across its 52-week range of $2.54 to $7.18, ANNX sits at the 32.5% percentile with a 14-day RSI of 52.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.54 to $4.56).
ANNX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ANNX stock moving today?
Why ANNX Stock advanced +1.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ANNX — Annexon Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:33:11Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ANNX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows:
- Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -24.53%. For a prospective investor, this means the business is currently consuming capital rather than generating it, so the valuation case depends on future cash generation that the source data does not project.
- Whale 13F Flow: 6 / 20. The rating cites institutional accumulation and options positioning. The underlying holdings detail is not present in the holders section, so the investor cannot verify the direction or size of institutional conviction from this dossier.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this is the lowest-scoring pillar and references an SEC Form 4 and Congressional PTR cluster flow. The lower score signals weak insider-side confidence relative to the other pillars.
- Macro Regime Fit: 5 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 means the stock is expected to move in line with the broad market, so it offers no defensive cushion; its risk is driven by company-specific cash burn.
- Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. This is the highest pillar but still moderate. The Piotroski score of 2/9 is weak, and it indicates limited improvement across profitability, leverage, and efficiency signals.
Investor implications: The main upside driver is a turn in cash generation, which the data does not show. The valuation tradeoff is that the market cap of $760.2M sits against sustained negative operating income and free cash flow, so the investor is effectively pricing in a future inflection. The 52-week range of $2.54 - $7.18 shows substantial price volatility, with the current price of 4.01 sitting in the middle of that range. The overall Roarable verdict is that the risk profile is elevated, and the rating advises avoidance on current data.
Business
Annexon Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it carries a market capitalization of $0.8B. The source data does not describe its products, customers, or revenue model. The reported revenue of $0.0M across the periods provided indicates no current revenue generation per the SEC financials.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-216.4M | $-206.7M | N/A | $-186.5M | $162.1M | N/A |
| FY 2024 | $0.0M | $-154.1M | $-138.2M | N/A | $-118.0M | $49.5M | N/A |
| FY 2023 | $0.0M | $-143.7M | $-134.2M | N/A | $-121.1M | N/A | N/A |
Per the SEC financials, operating losses widened from $-143.7M in FY 2023 to $-216.4M in FY 2025, and net losses followed the same direction. Gross, operating, and net margins are each reported at 0% per the market data, consistent with zero revenue. Per the Roarable RQD rating, ROIC is -35%, Altman Z-Score is 2.5, and Piotroski F-Score is 2/9. Cash rose to $162.1M in FY 2025 from $49.5M in FY 2024, while debt is not available in source data. Debt/Equity is 0.5 per the rating.
Recent Catalysts & News Wire Analysis
- Per the news wire, three items relate to ANNX: a CNN market-action item (1h ago, YELLOW), a Moomoo options-chain item (3h ago, YELLOW), and a Simply Wall St item (6h ago, GREEN, flagged CATALYST) titled around needing to drive business growth carefully.
- The catalyst items are generic market-coverage summaries. The source data does not specify a trial readout, regulatory event, partnership, or financing.
- Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals.
- Risk watch: The Simply Wall St headline's framing points to growth execution as an open question, consistent with the zero-revenue financials.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links. Not available in source data for upstream suppliers, downstream customers, or sector correlations beyond the stated Health Care and Biotechnology classification. The investor should watch for any future disclosure of partnerships or licensing arrangements, since the absence of links means no second-order ripple effects can be mapped from this dataset.
Open Questions
- What is the company's development pipeline and expected timing of any clinical or regulatory milestones?
- What is the current debt balance, since the financials report debt as N/A while the rating cites Debt/Equity of 0.5?
- What is the cash runway at the current burn rate relative to the $162.1M cash balance reported for FY 2025?
- What institutional holders drive the whale 13F flow pillar, and what is the direction of their positioning?
- What drove the sequence of insider Form 4 and Congressional PTR filings that the rating references?
ANNX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Annexon Inc. (ANNX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE CNN • 17h ago
symbol__ Stock Quote Price and Forecast CNN report covering Annexon Inc. (ANNX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 20h ago
Annexon(ANNX) Stock Options Chain | Quotes & News Moomoo report covering Annexon Inc. (ANNX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 23h ago
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully Simply Wall St report covering Annexon Inc. (ANNX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 5d ago
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im
🟡 MARKET WIRE Benzinga • 6d ago
Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will
🟢 CATALYST Benzinga • 15d ago
Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
🟢 CATALYST Benzinga • 15d ago
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25 HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
🟡 MARKET WIRE Yahoo • 17d ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ANNX Bull vs. Bear Conversation Board — What's Your Call at $4.05?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANNX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $3.53 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ANNX (E • RQD 30/100) a Buy at $4.01?
Welcome to the ANNX (Annexon Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $3.37 (-16.0%)
Spot @ $4.01 Pump the brakes on ANNX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ANNX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Annexon Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $4.77 (+19.0%)
Spot @ $4.01 ANNX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ANNX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.01 (52-wk range $2.54 - $7.18), any beat on forward guidance forces shorts and underweight funds to chase.